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The low-molecular-mass insulin-like growth factor-binding protein (IGF-BP) and placental protein 12 (PP12) are identi- 
cal proteins that are present in human serum, amniotic fluid, secretory endometrium and decidua. IGF-BP/PPIZ is be- 
lieved to act as an autocrine or paracrine regulator of cell growth. A cDNA clone encompassing the entire protein coding 
region of this protein was isolated from a human decidual cDNA library. The authenticity of the cDNA was verified 
by in vitro transcription/translation experiments and by the identity of the 10 N-terminal amino acids deduced for the 
mature peptide with those obtained by direct protein sequencing. The amino acid sequence indicates that pre-IGF-BP/ 
PPI 2 consists of 259 amino acid residues. The putative signal peptide is 25 residues long, and the mature protein thus 
contains 234 amino acids and has a molecular mass of 25293 Da. The sequence is very cysteine-rich at the N-terminus 
after which there are regions of clustered Pro, Glu, Ser and Thr residues (so-called PEST regions), which exist in proteins 
with short half-lives. The amino acid sequence also includes an Arg-Gly-Asp tripeptide that may function as a cell recog- 
nition signal. The IGF-BP/PPIZ gene encodes a single 1.6 kb mRNA species that is expressed in decidua. secretory endo- 
metrium. liver and a human hepatoma cell line (HepG2). Southern blot analysis suggests that there is a single IGF-BP/ 
PP 12 gene in the human genome. 
Insulin-like growth factor-binding protein; Placental protein 12; Amino acid sequence; mRNA expression 
1. INTRODUCTION 
Insulin-like growth factors 1 and 2 (IGF-I and 
IGF-II) interact with soluble extracellular binding 
proteins (IGF-BPS) the exact biological functions 
of which are poorly understood [l]. In man, the 
main circulating IGF-BP is a growth hormone- 
dependent macromolecule with a molecular mass 
of about 150 kDa [2]. Another class of IGF-BP, 
with molecular mass estimates from 25 to 45 kDa, 
is present in human serum and amniotic fluid [3,4]. 
It is also synthesized and secreted by a human 
hepatoma cell line, HepG2 [5]. A glycoprotein 
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termed placental protein 12 (PP12) was originally 
isolated from soluble extracts of human placenta 
and fetal membranes but was subsequently shown 
to be synthesized in secretory endometrium [6,7], 
dedicua [8] and granulosa cells [9], but not in the 
placenta [8]. PP12 is present in serum of healthy 
men and women, its concentration increases dur- 
ing pregnancy [IO] and is apparently regulated by 
insulin [1 11. PP12 binds avidly IGF-I and IGF-II 
[ 121. By all available criteria, including the 
molecular mass estimation by SDS-polyacrylamide 
gel electrophoresis, amino acid composition, N- 
terminal amino acid sequence and ligand-binding 
properties, PP12 and the smaller IGF-BP are iden- 
tical [5,12-141. Here, we use therefore the term 
IGF-BP/PP12 for this protein. We have isolated a 
cDNA clone for this protein, determined its com- 
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plete amino acid sequence and studied the sites of 
IGF-BP/PP 12 mRNA expression. 
2.5. RNA blot hybridization analysis 
2. MATERIALS AND METHODS 
2.1. Preparation of a human decidual cDNA library 
Human decidual RNA was isolated by the LiCI-urea method 
[15] and enriched in poly(A)+ RNA by two cycles of oligo(dT)- 
cellulose chromatography [16]. Synthesis of double-stranded 
cDNA was carried out according to Gubler and Hoffman [17]. 
The cDNAs were methylated and ligated to EcoRI linkers. 
After cleavage with EcoRl, the linker-containing cDNAs were 
ligated to EcoRI-cleaved, alkaline phosphatase-treated Agtll 
arms (Statagene, La Jolla, CA). The DNA was packaged in 
vitro and amplified in Escherichia co/i Y1088 cells. 
Samples of apparently normal human liver were obtained 
from a female patient undergoing hepatic resection because of 
hepatocellular carcinoma. Normal human renal and adrenal 
tissue were obtained from nephrectomies performed for renal 
cancer. Decidual samples were obtained from women 
undergoing legal abortions at the lO_12th week of pregnancy 
and from women undergoing caesarean section at the 40th week 
of pregnancy. Endometrial tissue was from curettage samples 
taken for medical reasons. Poly(A)-containing RNA samples 
(2 pg) were fractionated on 0.6% agarose gels containing 2.2 M 
formaldehyde [29] and transferred to nitrocellulose filters. 
Hybridization of the filter-bound RNA with the “P-labelled 
IGF-BP/PP12-cDNA and washing of the filters were carried 
out as described by Thomas (301. Autoradiography of the dried 
filters was conducted by exposing them to Kodak XAR film for 
1-3 days at - 70°C. 
2.2. Screening of the cDNA library 
About IO5 phage plaques were plated on E. coli Y 1090 cells 
and probed [18] with two polyclonal antisera for IGF-BP/PP12 
raised in rabbits, 245 11 [19] and 461ZA (obtained from Dr 
Hans Bohn, Behringwerke AG, Marburg, FRO). Five 
recombinant phage clones which were strongly positive with 
both antisera were plaque purified and phage DNA isolated 
[201. 
2.6. Southern blotting of genomic DNA 
Human leukocytic DNA was digested with the different 
restriction enzymes, fractionated by gel electrophoresis on 
0.6% agarose and transferred to nitrocellulose filters. 
Hybridization, washing and autoradiography of the filters were 
conducted as described above for the RNA blots. 
2.3. DNA sequencing 3. RESULTS 
The longest cDNA insert was cleaved with Aval, Psfl, Accl, 
BarnHI and Hincll restriction enzymes, which were found to 
have unique sites in the cDNA in preliminary restriction 
mapping analysis. The fragments were subcloned into the 
corresponding sites of pGEM-3 blue vector. Sequencing of 
double-stranded DNA was performed by the dideoxynucleotide 
chain-termination method using SequenaserM enzyme (US 
Biochemical Corp., Cleveland, OH) and SP6 and T7 promoter 
primers [21,22]. In addition, two internal 20-mer 
oligonucleotide primers were synthesized to permit unequivocal 
sequence determination for both strands of the IGF/BP/PP12 
cDNA insert. 
Screening of human decidual cDNA library with 
the two IGF-BP/PP12 antisera yielded five im- 
munopositive clones. EcoRI digestion of the 
plaque-purified phage DNA preparations revealed 
inserts that ranged from 700 to 1500 base pairs in 
size and cross-hybridized with each other (not 
shown). The longest insert of a clone designated 
IGF-BP/PP12-5 was subcloned into plasmid vec- 
tors and used for subsequent studies. 
DNA sequences were aligned and joined using DBSTART, 
DBUTIL, and DBAUTO programs [23]. Comparison of two 
sequences was performed using the FASTN and FASTP 
programs [24]. A hydropathicity plot of the amino acid 
sequence deduced from the cDNA was constructed with the 
algorithm described by Kyte and Doolittle [25], using a window 
of 7 amino acids. Comparison of IGF-BP/PPlZ cDNA and 
deduced amino acid sequences to known protein sequences was 
performed by searching the currently available data resources. 
2.4. In vitro transcription/translation studies 
The isolated cDNA was cloned in both orientations into the 
EcoRI site of pGEM-3 blue, the chimeric plasmids were 
linearized with SalI, and capped sense and complementary 
RNA strands were synthesized using T7 RNA polymerase in the 
presence of 5’-7meGpppG-3’ [26]. The RNAs were translated 
in vitro in a reticulocyte lysate (Bethesda Research Labs, 
Gaithersburg, MD) with [35S]methionine as the labeled amino 
acid. Radioactive peptides were analyzed, before and after 
immunoprecipitation with anti-IGF-BP/PPIZ antiserum, on 
10% polyacrylamide gels containing 0.1% SDS [27], essentially 
as described [28]. 
Cell-free translation of the capped RNAs 
transcribed from both strands of the cDNA 
showed that each strand supported synthesis of a 
labeled peptide with molecular masses of about 33 
and 20 kDa, respectively (fig.lA). Only the 
33 kDa peptide was immunoprecipitable with anti- 
IGF-BP/PP12 antiserum; the antibody precipitated 
100% of this peptide as judged by radioactivity 
measurements. The same antiserum immuno- 
precipitated from the labeled translation products 
of decidual poly(A) RNA a peptide whose mobility 
on polyacrylamide gel electrophoresis was identical 
with the 33 kDa peptide encoded by the synthetic 
RNA (fig.lB). These data provided strong 
evidence that the cDNA corresponds to IGF- 
BP/PP12 and contains the entire protein coding 
sequence. 
DNA sequencing indicated that the IGF- 
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Fig.1. Analysis of cell-free translation products encoded by 
RNAs transcribed from IGF-BP/PPlZ cDNA and by poly(A)- 
containing RNA from human decidua. Capped RNAs 
corresponding to both strands of the cDNA were synthesized 
with Tr RNA polymerase as described in section 2. The peptides 
labelled with [3SS]methionine were analyzed, before and after 
immunoprecipitation with IGF-BP/PPlZ antiserum, on 10% 
polyacrylamide gels containing 0.1% SDS. (A) Lanes: l-5, no 
exogenous RNA added; 2,6, reticulocyte RNA (1 pg); 3,7, IGF- 
BP/PPIZ RNA (sense strand, 100 ng); 4.8, IGF-BP/PPlZ 
RNA (complementary strand, 100 ng). Lanes l-4 correspond 
to 1/5th of the translated peptides before immunoprecipitation 
and lanes 5-8 to 315th of the peptides after immuno- 
precipitation. (B) Immunoprecipitated products from cell-free 
translation of decidual poly(A) RNA. Lanes: 1, decidual RNA 
(I pg); 2, reticulocyte RNA (1 pg). Exposure times during 
fluorography were 2 h and 3 days for A and B, respectively. 
BP/PP12 cDNA is 1443 nucleotides long and con- 
tains an open reading frame of 777 bases encoding 
a 259-amino-acid-long peptide (fig.2) on the strand 
that supported cell-free translation of the 33 kDa 
peptide immunoprecipitable with IGF-BP/PP12 
antiserum (fig. 1A). The predicted molecular mass 
of the peptide deduced from the cDNA sequence is 
27926 Da. The amino acid contains a 25residue- 
long putative signal peptide rich in hydrophobic 
amino acids (fig.2). The 10 N-terminal amino acids 
of the mature protein (APWQCAPCSA) are iden- 
tical with those published for the N-termini of 
human amniotic fluid IGF-BP [ 131 and PP12 [ 141, 
thus confirming the authenticity of the cDNA 
clone. The mature peptide has a calculated 
molecular mass of 25293 Da. The IGF-BP/PP12 
peptide is very rich in Cys, Pro, Glu and Asp 
residues, which may explain its aberrant mobility, 
even in non-glycosylated form, on SDS-containing 
polyacrylamide gels; the cell-free translation pro- 
duct has an apparent molecular mass of 33 kDa as 
opposed to 27.9 kDa deduced from the cDNA. 
The peptide sequence does not contain recognition 
sequences for N-linked glycosylation (Asn-X-Ser 
or Asn-X-Thr) but has regions rich in Ser and Thr 
(e.g. residues 101-102, 131-132, 168-169, 
194-195) which could serve as acceptors for O- 
linked carbohydrates. 
After the first 80 N-terminal residues of the 
mature peptide the amino acid sequence of IGF- 
BP/PP12 contains several regions very rich in Pro, 
Glu, Ser and Thr residues (fig.2). Clusters of these 
amino acids are known to be present in proteins 
with short intracellular half-lives [31], and have 
been termed PEST regions. Of particular 
significance is the sequence encompassing residues 
89-l 14 (HAAEAGSPESPESTEITEEELLDNFH) 
which is a typical PEST sequence in that it contains 
clusters of the above-mentioned four residues and 
is flanked with a positively charged amino acid 
(His) on each side. An Arg-Gly-Asp sequence, 
which has been shown to serve as a cell attachment 
site of several proteins [32], is present close to the 
carboxy-terminal end of the protein (residues 
221-223). 
The hydropathicity profile of the pre-IGF- 
BP/PP12 is illustrated in fig.3. The signal peptide 
region is very hydrophobic as expected. The other 
relatively hydrophobic region of the protein is also 
at its N-terminus and covers residues 30-50, which 
contains a cluster of 5 cysteines. It is tempting to 
speculate that this part of the peptide is involved in 
ligand binding. The rest of the protein sequence 
comprises several very hydrophilic regions that are 
mainly due to clustered Glu residues. 
The 1443-nucleotide-long IGF-BP/PP12 cDNA 
sequence has 5 ’ - and 3 ’ -noncoding regions of 102 
and 564 bases in length, respectively (fig.2). The 
sequence flanking the initiation codon, 
GGAG(ATG)T, agrees in part with the consensus 
sequence of Kozak [33]. A putative polyadenyla- 
tion signal (AATAAA) starts 13 nucleotides from 
the 3’-end of the cDNA, i.e. the cloned sequence 
is missing a few nucleotides between the 
polyadenylation signal and the poly(A) tail. 
Whether the GC-rich 5’-noncoding region of the 
cDNA reaches the cap site of IGF- 
BP/PP12-mRNA is not known, and primer exten- 
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LENGTH (basopairs) 
Fig.2. Sequencing strategy and nucleotide and deduced amino acid sequences of IGF-BP/PP12 cDNA. (A) Arrows show the direction 
and extent of each sequence determination. The locations of the two internal primers (1,2) are depicted by the short arrows. Restriction 
sites shown in the map are those used for subcloning. (-) 5’- and 3’-nontranslated regions; (u) the protein-coding sequence 
with the cross-hatched area corresponding to the signal peptide. (B) Nucleotide sequence and deduced amino acid sequence. The N- 
terminal amino acid residues of the mature peptide identical with those determined by direct protein sequencing are depicted by a thick 
line under the sequence. The residues corresponding to the PEST region are identified by a thin line. The poly(A) addition/termination 
signal (AATAAA) is underlined by a dashed line. 
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Fig.3. Hydropathicity plot of IGF-BP/PPlZ amino acid 
no.1. 
sequence. The algorithm described by Kyte and Doolittle [25] 
and a window of 7 amino acids were used to construct the plot. 
The numbers in the abscissa refer to those of the amino acids, 
with the amino-terminal residue of the mature peptide being 
sion and/or direct RNA sequencing studies remain 
to be carried out. There are four copies of the se- 
quence motif ATTTA in the 3 ‘-nontranslated 
region of IGF-BP/PP12 mRNA (fig.2), suggesting 
that, in addition to the encoded protein, the 
mRNA also has a short half-life [34]. 
As mentioned above, the RNA corresponding to 
the opposite strand of the cDNA also encoded a 
peptide during cell-free translation that, however, 
was not immunoprecipitated with IGF-BP/PP12 
antiserum (fig. 1A). This unexpected finding may 
be explained by the presence of two overlapping 
open reading frames on the opposite strand, cor- 
responding to nucleotides 660 -+ 109 and 542 
-+ 1. The first could encode the 20 kDa peptide 
(fig.lA), as the open reading frame has an initia- 
tion Met codon 65 nucleotides from the beginning 
of its sequence (nucleotides 597-595) and poten- 
tially codes for a peptide with 163 amino acid 
residues. 
RNA from a number of human tissues, in- 
cluding liver, kidney, adrenal, endometrium, 
placenta and decidua, as well as RNA extracted 
from a human hepatoma cell line (HepG2), were 
analyzed for the presence of IGF-BP/PP12 mRNA 
sequences by RNA blot hybridization (fig.4). 
When present, a single mRNA species with a 
molecular size of 1.6 kb was found. This mRNA 
kb 
os- 
Fig.4. RNA blot hybridization analysis of poly(A)-containing 
RNA from human tissues. RNA was isolated from the 
Molecular size markers are shown on the left. 
following sources: HepG2 cells (lane l), liver (2), kidney (3), 
adrenal (4), secretory endometrium (5). proliferative 
endometrium (6), placenta (7), late-pregnancy decidua (8) and 
early-pregnancy decidua (9). RNA samples (2 /g/lane) were 
fractionated by electrophoresis on 0.6% agarose containing 
2.2 M formaldehyde, transferred to nitrocellulose filter and 
hybridized with the “P-1abelled IGF-BP/PP12 cDNA probe. 
Fig.5. Southern blot analysis of human DNA. Samples of DNA 
(IO/g/lane) were digested with Bglll (lane I), EcoRV (2). PvuII 
(3), Sac1 (4). BamHl (5) and EcoRl (6). fractionated by 
electrophoresis on 0.6% agarose, transferred to nitrocellulose 
filter and hybridized with the ‘ZP-labelled IGF-BP/PPlZ cDNA 
probe. Molecular size markers are shown on the left (kb = 
thousands of base pairs). 
species was most abundant in decidua at term and 
a considerable amount was also present in decidua 
of early pregnancy and secretory endometrium; no 
hybridizable mRNA was found in proliferative en- 
dometrium, placenta at term, kidney or adrenal. 
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HepG2 cells expressed IGF-BP/PP12 mRNA at 
concentrations clearly higher than those in normal 
human liver cells. 
Southern blot analysis of human leukocytic 
DNA using the restriction enzymes BglII, EcoRV, 
PvuII, SacI, BumHI and EcoRI revealed the 
presence of one or two hybridizable DNA 
fragments with molecular sizes of 2.5-10 kb 
(fig.5). These data are compatible with the 
assumption that there is a single IGF-BP/PP12 
gene in the human genome. 
4. DISCUSSION 
In this communication, we report cloning of a 
cDNA corresponding to the low-molecular mass 
IGF-binding protein, also known as placental pro- 
tein 12. The authenticity of the cDNA was verified 
by cell-free transcription/translation experiments 
and by the identity of the 10 N-terminal amino acid 
residues deduced from the cDNA and obtained by 
direct protein sequencing. A single copy of the 
IGF-BP/PP12 gene appears to be present in the 
human genome, and its 1.6 kb mRNA is expressed 
in uterine cells. However, the mRNA was detect- 
able only in decidua and secretory endometrium 
but not in proliferative endometrial tissue, sug- 
gesting that the expression of this gene is under the 
control of progesterone in human uterus. This is in 
agreement with previous studies in which im- 
munoreactive protein concentrations in the uterus 
were investigated [7,35]. Furthermore, human liver 
and a hepatoma-derived cell line (HepG2) express 
IGF-BP/PP12 mRNA, suggesting that at least part 
of serum PP12 originates from the liver. Several 
other human tissues, including the placenta, do not 
express this gene. 
Comparison of the IGF-BP/PP12 sequence to 
other reported protein sequences in most current 
data resources did not revea1 any striking 
homologies. However, a stretch extending from 
residue 59 to 79 of IGF-BP/PP12 exhibited a 43% 
identity with a portion (amino acids 133-153) of 
human transforming-growth factor cy precursor 
[36], and another stretch from residue 151 to 165 
showed a 47% similarity with a region (amino 
acids 4-18) of human plasma retinol-binding pro- 
tein [37]. It remains to be investigated whether 
these limited similarities have any functional im- 
plications. 
300 
The primary amino acid sequence of IGF- 
BP/PP12 revealed some interesting features that 
may be of functional and regulatory importance. 
First, the peptide is very cysteine-rich, with 11 of 
the 18 Cys residues being located among the 60 N- 
terminal amino acids. A hydrophobic domain 
covering residues 30-50 is particularly abundant in 
cysteines; the suggestion that this domain is in- 
volved in the ligand binding of the protein is in 
agreement with the previous demonstration that 
the N-terminal half of the PP12 is responsible for 
its IGF-I-binding activity [38]. Although the 
primary structure of IGF-BP/PP12 does not show 
any apparent similarity with those of the receptors 
for IGF-I [39] or IGF-II [40], the putative ligand- 
binding sites of these two other IGF-binding pro- 
teins also contain clusters of Cys residues. 
Second, the protein contains a number of 
regions rich in Pro, Glu, Ser and Thr residues; one 
of these is a particularly typical PEST region 
(residues 89-114). The presence of this sequence 
along with the negatively charged nature of the 
protein suggest that its intracellular half-life is very 
short [3 I]. Many other proteins with PEST regions 
and rapid turnover rates have been shown to 
possess important intracellular regulatory func- 
tions. These include proteins such as c-myc, c-fos, 
v-myb, heat-shock protein 70 and ornithine decar- 
boxylase and hydroxymethylglutaryl-CoA reduc- 
tase [31]. Although the intracellular half-life of 
IGF-BP/PP12 is currently unknown, its fast rate 
of degradation may be inferred from the findings 
that the circulating IGF-BP/PP12 levels exhibit a 
clearcut diurnal variation [41,42]. Finally, in addi- 
tion to being responsible for the rapid turnover 
rate of the protein, the hydrophilic C-terminal half 
could also be the region through which this protein 
adheres to the cell surface [43], since it includes the 
Arg-Gly-Asp (RGD) tripeptide known to represent 
the cell attachment site in proteins such as 
fibronectin, vitronectin and fibrinogen [32]. 
The function of the low-molecular-mass IGF-BP 
has remained poorly understood. While some 
studies have suggested that IGF-BPS may increase 
the amount of IGF-I that binds to the IGF recep- 
tors [43] and enhance the biologic response to IGF- 
I [44], other investigations have indicated that 
these binding proteins may in fact inhibit the in- 
teraction of IGF-I with its receptor and thus at- 
tenuate its biological function [45,46]. It is possible 
Volume 236, number 2 FEBS LETTERS August 1988 
that IGF-BPS represent paracrine regulatory pro- 
teins whose ultimate physiological effects, whether 
stimulatory or inhibitory, depend on their concen- 
tration, the type of the target cells and the presence 
of other available growth regulators. The present 
cloning of a full-length cDNA for IGF-BP/PP12 
provides an opportunity to examine the sites and 
regulation of expression of the IGF-BP/PP12 gene 
under different experimental conditions, delineate 
the functional domains of the protein using site- 
directed mutagenesis, and overexpress the native 
or mutated proteins in cells that are regulated by 
insulin-like growth factors. 
Acknowledgements: We thank MS Meeri Lappalainen and MS 
Kaija Kettunen for expert technical assistance. MS Jean Schweis 
provided invaluable secretarial help. This work was supported 
by grants from the Simpson Foundation, the Medical Research 
Council of the Academy of Finland, the Sigrid Juselius Founda- 
tion and the University of Helsinki. 
REFERENCES 
[II 
PI 
[31 
[41 
[51 
Kd 
[71 
[81 
[91 
[lOI 
1111 
Daughaday, W.H., Ward, A.P., Goldberg, A.C., 
Trivedi, B. and Kapadia, M. (1982) J. Clin. Endocrinol. 
Metab. 55, 916-921. 
Baxter, R.C., Martin, J., Tyler, M. and Howden, M. 
(1986) Biochem. Biophys. Res. Commun. 139, 
1256-1261. 
Chochinov, R.H., Mariz, I.K., Hajek, A.S. and 
Daughaday, W.H. (1977) J. Clin. Endocrinol. Metab. 44, 
902-908. 
Povoa, G., Roovete, A. and Hall, K. (1984) Acta 
Endocrinol. 107, 563-570. 
Povoa, G., Isaksson, M., JGrnvall, H. and Hall, K. (1985) 
Biochem. Biophys. Res. Commun. 128, 1071-1078. 
Bohn, H. and Kraus, W. (1980) Arch. Gynecol. 229, 
279-291. 
Rutanen, E.-M., Koistinen, R., SjGberg, J., Julkunen, 
M., WahlstrGm, T., Bohn, H. and Sepptilti, M. (1986) 
Endocrinology 118, 1067-1071. 
Rutanen, E.-M., Koistinen, R., Wahlstram, T., Bohn, 
H., Ranta, T. and SeppllB, M. (1985) Endocrinology 116, 
1304-1309. 
Sepp&, M., Wahlstriim, T., Koskimies, A.I., Tenhunen, 
A., Rutanen, E.-M., Koistinen, R., Huhtaniemi, I., 
Bohn, H. and Stenman, U.-H. (1984) J. Clin. Endocrinol. 
Metab. 58, 505-510. 
Rutanen, E.-M., Bohn, H. and Sepp%, M. (1982) Am. 
J. Obstet. Gynecol. 144, 460-463. 
Suikkari, A.M., Koivisto, V.A., Rutanen, E.-M., Yki- 
Jlrvinen, H., Karonen, S.-L. and Sepp?il%, M. (1988) J. 
Clin. Endocrinol. Metab. 66, 266-272. 
[I51 
[I61 
1171 
[I81 
[I91 
PO1 
[211 
WI 
v31 
v41 
1251 
P61 
1271 
WI 
v91 
[301 
[311 
[321 
[331 
[341 
[351 
[361 
[371 
[381 
I391 
1401 
Koistinen, R., Huhtala, M.-L., Stenman, U.-H. and 
Sepplki, M. (1987) Clin. Chim. Acta 164, 293-303. 
Povoa, G., Enberg, G., Jiirnvall, H. and Hall, K. (1984) 
Eur. J. Biochem. 144, 199-204. 
Koistinen, R., Kalkkinen, N., Huhtala, M.-L., Sepplll, 
M., Bohn, H. and Rutanen, E.-M. (1986) Endocrinology 
118, 1375-1378. 
Auffray, C. and Rougeon, F. (1980) Eur. J. Biochem. 
107, 303-314. 
Aviv, H. and Leder, P. (1972) Proc. Natl. Acad. Sci. USA 
69, 1408-1412. 
Gubler, U. and Hoffman, B.J. (1983) Gene 25, 263-269. 
Young, R.A. and Davis, R.W. (1983) Science 222, 
778-782. 
Koistinen, R., Stenman, U.-H., Alfthan, H. and SeppPl& 
M. (1987) Clin. Chem. 33, 1126&1128. 
Maniatis, T., Fritsch, E.F. and Sambrook, J. (1982) 
Molecular Cloning: A Laboratory Manual, Cold Spring 
Harbor Laboratory Press, NY. 
Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Proc. 
Natl. Acad. Sci. USA 74, 5463-5467. 
Chen, E.Y. and Seeburg, P.H. (1985) DNA 4, 165-170. 
Staden, R. (1982) Nucleic Acids Res. 10, 4731-4751. 
Lipman, D.J. and Pearson, W.D. (1985) Science 227, 
1435-1441. 
Kyte, J. and Doolittle, R.F. (1982) J. Mol. Biol. 157, 
103-132. 
Nielsen, D.A. and Shapiro, D.J. (1986) Nucleic Acids 
Res. 14, 5936. 
Laemmli, U.K. (1970) Nature 227, 680-687. 
Kontula, K.K., Torkkeli, T.K., Bardin, C.W. and Jinne, 
O.A. (1984) Proc. Natl. Acad. Sci. USA 81, 731-735. 
Rave, N., Crkvenjakov, R. and Boedtker, H. (1979) 
Nucleic Acids Res. 6, 3559-3567. 
Thomas, P.J. (1980) Proc. Natl. Acad. Sci. USA 77, 
5201-5205. 
Rogers, C., Wells, R. and Rechsteiner, M. (1986) Science 
234, 364-368. 
Ruoslahti, E. and Pierschbacher, M.D. (1986) Cell 44, 
517-518. 
Kozak, M. (1984) Nucleic Acids Res. 12, 857-872. 
Shaw, G. and Kamen, R. (1986) Cell 46, 659-667. 
Wahlstrom, T. and SeppllB, M. (1984) Fertil. Steril. 41, 
78 I-784. 
Derynck, R., Roberts, A.B., Winkler, M.E., Chen, E.Y. 
and Goeddel, D.V. (1984) Cell 38, 287-297. 
Godovac-Zimmermann, J., Conti, A., Liberatori, J. and 
Braunitzer, G. (1985) Biol. Chem. Hoppe-Seyler 366, 
431-434. 
Huhtala, M.-L., Koistinen, R., Palomtiki, P., Partanen, 
P., Bohn, H. and Sepp%, M. (1986) Biochem. Biophys. 
Res. Commun. 141, 263-270. 
Ullrich, A., Gray, A., Tam, A.W., Yang-Feng, T., 
Tsubokawa, M., Collins, C., Henzel, W., Le Bon, T., 
Kathuria, S., Chen, E., Jacobs, S., Francke, U., 
Ramachandran, J. and Fujita-Yamaguchi, Y. (1986) 
EMBO J. 5, 2503-2512. 
Morgan, D.O., Edman, J.C., Standring, D.N., Fried, 
V.A., Smith, M.C., Roth, R.A. and Rutter, W.J. (1987) 
Nature 329, 301-307. 
301 
Volume 236, number 2 FEBS LETTERS August 1988 
[41] Rutanen, E.-M., Seppala, M., Pietila, R. and Bohn, H. 
(1984) Placenta 5, 243-248. 
(421 Baxter, R.C. and Cowell, C.T. (1987) J. Clin. 
Endocrinol. Metab. 65, 432-440. 
[43] Clemmons, P.R., Elgin, R.G., Han, V.K.M., Casella, 
S.J., D’Ercole, A.J. and Van Wyk, J.J. (1986) J. Clin. 
Invest. 77, 1548-1556. 
[44] Elgin, R.G., Busby, W.H. jr and Clemmons, D.R. (1987) 
Proc. Natl. Acad. Sci. USA 84, 3254-3258. 
1451 Knauer, D.J. and Smith, G.L. (1980) Proc. Natl. Acad. 
Sci. USA 77, 7252-7255. 
[46] Rutanen, E.-M., Pekonen, F. and Makinen, T. (1988) J. 
Clin. Endocrinol. Metab. 66, 173-180. 
302 
